Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Condition: Primary Central Nervous System Lymphoma Interventions: Drug: Orelabrutinib; Drug: Pomalidomide; Drug: Rituximab; Drug: Methotrexate Sponsors: Peking Union Medical College Hospital; Beijing Tiantan Hospital; Sanbo Brain Hospital Capital Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials